Home > Boards > US OTC > Medical - Drugs >


Add AVXT Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 3/3/2021 4:35:51 PM - Followers: 35 - Board type: Free - Posts Today: 0


Industry Center - Biotechnology

Contact Information
Address: 2000 Hamilton St., Ste. 204
Philadelphia, PA 19130
Phone: 215-241-9760
Fax: 215-241-9684
Key People
CEO: Adele Sommerfeld
BOD: Andrew W. Dahl Sc.D.; Serge Morrell
AVAX Technologies wants to turn cancer cells into cancer fighters. The company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate MVax is intended as a treatment for late-stage melanoma. The company is also developing vaccine candidates to fight ailments such as ovarian cancer (OVax) and non-small cell lung cancer (LungVax).
Business Summary  

AVAX Technologies, Inc., a development stage biotechnology company, together with its subsidiaries, engages in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer in the United States and Europe. The company's autologous cell vaccine candidates include M-Vax under Phase III clinical status, which is used for the treatment of melanoma; L-Vax under Phase I-II clinical status that is used for the treatment of non-small cell lung cancer; and O-Vax under Phase I-II clinical status, which is used for the treatment of ovarian cancer. It also offers biological manufacturing services to other biotechnology and pharmaceutical companies; and contract manufacturing services in for cell and gene therapy, and biological products in France. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.


AVAX Technologies, Inc. Files Form 10 With SEC

Press Release Source: AVAX Technologies, Inc. On Friday February 4, 2011, 12:41 pm EST

PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink Sheets:AVXT.pk - News) ("AVAX" or the "Company") today announced that it filed a Form 10 with the Securities and Exchange Commission ("SEC").  Upon the effectiveness of this Form 10, AVAX will once again become a publicly reporting company.  The Company intends to seek to have its common stock trade on the Over-the-Counter Bulletin Board.

The Company's Form 10, which contains among other things, recent information about the Company's business, operations, financial results and capitalization, can be accessed through the website maintained by the SEC at www.sec.gov.

About AVAX Technologies, Inc.

AVAX Technologies, Inc. is a biotechnology company headquartered in Philadelphia, PA.   The Company is engaged in the research and clinical and commercial development of biological products and cancer therapeutics.

The Company's AC Vaccine platform is a therapeutic cancer vaccine.

Forward-Looking Statements

Certain statements in this release are "forward-looking" statements.   Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. These statements include, but are not limited to, the Company's immediate need to obtain additional funding to continue to finance the Company, the Company's plans, objectives, projections, expectations and intentions such as those relating to the future development of M-VAX® and its other vaccine candidates, as well as other important factors discussed in the Company's Form 10.   The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events. 


Press Releases & AVAX Information:


2/4/2001: AVAX Technologies, Inc. Files Form 10 With SEC












AVAX Announces Settlement Agreement with Cancer Treatment Centers of America and Approves $45 Million Private Placement Financing


Published: Aug 4, 2015 7:31 p.m. ET


PHILADELPHIA, Aug 04, 2015 (BUSINESS WIRE) -- AVAX Technologies, Inc., (“AVAX” or “The Company”) (AVXT – OTCMKTS), a leading developer of proprietary cancer immunotherapy products, has signed a Settlement & Release Agreement with Cancer Treatment Centers of America Inc. (“CTCA”) to positively resolve the existing debt obligations owed to CTCA.

Under the terms of the Settlement Agreement, CTCA has agreed to settle its $5,826,464.73 Judgment against AVAX in exchange for 860,000 Series A Convertible Preferred Shares at a consideration of $5.00 per share, and a one-time payment of $1.5 million in cash. Firebird Management, a shareholder and a creditor of AVAX, has agreed to swap its outstanding debt for the Series A Convertible Preferred Shares also at a consideration of $5.00 per share.

Andrew Dahl, AVAX Board Member noted, “we are extremely happy to be able to move forward with the reorganization of AVAX’s balance sheet and look forward to re-commencing the important planned clinical trials at AVAX. Our previous work with CTCA on clinical programs has been very successful.”

Richard Rainey, Acting Chief Executive Officer of AVAX, stated, “We are pleased that throughout the development of our AC Vaccine® platform, all of our data has remained consistently positive and has supported further development of the treatment. We feel our immunotherapy platform is consistent with recently approved products and could be additive to the benefits achieved in helping patients with cancer.”

SGC Canada Inc., is acting on behalf of AVAX with its creditors in negotiating its informal restructuring plan. David Holden, the Senior Corporate Advisor of SGC states that “AVAX will be effectively debt-free once the Financial Restructuring & Refinancing Plan is completed.” The Board of AVAX has previously approved the engagement of Phoenix Corporate Finance Inc., a corporate finance firm which specializes in alternative financing, to advise, structure, and facilitate the distribution of a proposed Private Placement financing. through select securities dealers in the US and Canada. AVAX intends to raise $45 million to fund its next round of clinical testing through the issuance of the Series A Convertible Preferred Shares.




Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#1602   Bought Back In! Word Is Getting Out Regarding cuckoo 4 cocoa puffs 03/03/21 04:35:51 PM
#1601   Holy Crap I sold in the 002's!!!!! Damn it cuckoo 4 cocoa puffs 02/11/21 01:45:40 PM
#1600   Estimated Study Completion Date: January 2021 rikic 02/11/21 01:48:57 AM
#1599   It's A$k Smacking Time! cuckoo 4 cocoa puffs 12/18/20 03:29:22 PM
#1598   Will Today's Buy @ .0024 Be Tomorrows .24? cuckoo 4 cocoa puffs 12/18/20 09:39:57 AM
#1597   Some-Bod (s) R REALLY Trying to Keep A cuckoo 4 cocoa puffs 11/06/20 02:58:08 PM
#1596   The paper's getting thin @ .003; is a cuckoo 4 cocoa puffs 07/31/20 10:08:17 AM
#1594   Let's Clear Those 003's!!! cuckoo 4 cocoa puffs 07/06/20 12:19:55 PM
#1593   Nice Volume So Far Today 306k. Large Bids cuckoo 4 cocoa puffs 06/22/20 12:35:41 PM
#1592   4M share bid @ .0017 is sure sign cuckoo 4 cocoa puffs 05/28/20 03:06:27 PM
#1591   5.Key Vendors cuckoo 4 cocoa puffs 05/28/20 12:24:24 PM
#1590   Bring on the .003's!!! Woot Woot! cuckoo 4 cocoa puffs 03/26/20 01:39:03 PM
#1589   WTH? News??? cuckoo 4 cocoa puffs 03/05/20 04:01:34 PM
#1588   Not me Brotha I'm GEEKED UP 4 What's cuckoo 4 cocoa puffs 01/15/20 02:12:38 PM
#1587   Thought AVAX was dead and buried??? johnny canuck 12/09/19 11:38:53 AM
#1586   Emerging Cancer Vaccines Market to Develop New Growth cuckoo 4 cocoa puffs 11/22/19 11:17:48 AM
#1585   Should be avax johnny canuck 10/23/19 06:21:32 PM
#1584   Abscess merged with someone and went private. This johnny canuck 10/23/19 06:19:13 PM
#1583   Nice vol here today iateone2 10/23/19 03:30:25 PM
#1582   Definite upwards trend here; higher ask and thinning! cuckoo 4 cocoa puffs 10/23/19 02:21:46 PM
#1581   L2 keeps shifting look like she wants to go. iateone2 10/23/19 12:34:03 PM
#1580   this looks very thin iateone2 10/23/19 12:26:01 PM
#1579   Global Personalized Cancer Vaccine Market, Clinical Trials & cuckoo 4 cocoa puffs 10/23/19 12:22:50 PM
#1578   ReNewed interest in this Ticker; Something is brewing... cuckoo 4 cocoa puffs 10/23/19 12:16:56 PM
#1577   The Power of Immunotherapy! cuckoo 4 cocoa puffs 10/11/19 11:43:03 AM
#1576   Well, that was Firebird, because they pretty much medimpact 04/11/19 01:15:51 PM
#1575   So sad that they are gone as a powerbattles 04/11/19 01:08:27 PM
#1574   Startingboy is probably right in his posts below ... tencoin 04/11/19 07:14:23 AM
#1573   I was wonder how BioVaxys manage to transfer powerbattles 04/09/19 10:40:59 PM
#1572   You can contact Mr. Kovan with your words tencoin 01/25/19 07:15:45 AM
#1571   Well, you could contact Mr. Kovan again and medimpact 01/24/19 04:05:27 PM
#1570   thanks for sharing man. well it looks like startingboy 01/04/19 09:50:00 PM
#1569   I don't know if you owner AVAX shares tencoin 01/04/19 04:05:33 AM
#1568   not i don't to your first question,i just startingboy 12/28/18 01:48:36 PM
#1567   Thank you very much for links ... did tencoin 12/28/18 01:16:31 PM
#1566   https://biovaxys.com/ startingboy 12/28/18 01:17:00 AM
#1565   looks like dr berd & firebird fund move startingboy 12/28/18 01:13:51 AM
#1564   Question: If AVXT'S Outstanding share count is 142.61M, cuckoo 4 cocoa puffs 10/12/18 12:18:07 PM
#1563   They are no longer at their location. Type johnny canuck 09/04/18 11:53:27 AM
#1562   I'm loving it !!! Pharmazar 08/27/18 01:33:58 PM
#1561   Melanoma Global Market 2017: Key Players: AB Science, cuckoo 4 cocoa puffs 08/27/18 01:16:53 PM
#1560   For a dead ticker AVXT sure is showing cuckoo 4 cocoa puffs 08/27/18 01:04:10 PM
#1559   Volume traded today is over 2M. HMMMMMM......... cuckoo 4 cocoa puffs 08/27/18 01:02:37 PM
#1558   Thank you 4 the cheap shares @ .001 today! cuckoo 4 cocoa puffs 05/03/18 02:52:41 PM
#1557   They don't have any web site. how Kam8 04/16/18 11:29:48 AM
#1556   Great find tencoin! This could be OVAX..... cuckoo 4 cocoa puffs 04/16/18 09:36:17 AM
#1555   Hi Dear, why made you so confident about AVAX? Kam8 04/16/18 08:59:12 AM
#1554   HI Dear, Any comments on AVAX? Kam8 04/16/18 08:49:57 AM
#1553   Hi Dear, have you already invested AVAX? Kam8 04/16/18 08:48:09 AM
Consent Preferences